Drug delivery systems for the prevention and treatment of vascular diseases
OwnerMargaret Forney Prescottinventor
Life of this patent
Estimating the term…
Abstract
Provided are drug delivery systems for the prevention and treatment of proliferative diseases, particularly vascular diseases, comprising rapamycin or a rapamycin derivative having mTOR inhibiting properties, optionally in conjunction with one or more active co-agents.
Claims20
A drug delivery device or system comprising i) a medical device adapted for local application or administration of an active ingredient in hollow tubes and ii) an active ingredient comprising a therapeutic dosage of a rapamycin derivative having mTOR inhibiting properties or rapamycin, in conjunction with a therapeutic dosage of one or more active co-agents selected from an EDG-receptor agonist having lymphocyte depleting properties, a cox-2 inhibitor, pimecrolimus, a cytokine inhibitor, a chemokine inhibitor, an antiproliferative agent, a statin, a protein, growth factor or compound stimulating growth factor production that will enhance endothelial regrowth of the luminal endothelium, a matrix metalloproteinase inhibitor, a somatostatin analogue, an aldosterone synthetase inhibitor or aldosterone receptor blocker and a compound inhibiting the renin-angiotensin system, each being releasably affixed to the medical device.
A drug delivery device or system comprising i) a medical device adapted for local application or administration of an active ingredient in hollow tubes and ii) an active ingredient comprising a therapeutic dosage of a rapamycin derivative having mTOR inhibiting properties, in conjunction with a therapeutic dosage of one or more active co-agents selected from a calcineurin inhibitor and mycophenolic acid or a salt thereof or prodrug thereof, each being releasably affixed to the medical device.
A combination of rapamycin or a rapamycin derivative having mTOR inhibiting properties with pimecrolimus, an aldosterone synthetase inhibitor or an aldosterone receptor blocker, or with a compound inhibiting the renin-angiotensin system.
A method for preventing or treating smooth muscle cell proliferation and migration in hollow tubes, or increased cell proliferation or decreased apoptosis or increased matrix deposition in a subject in need thereof, comprising local administration of a therapeutically effective amount of an active ingredient comprising a rapamycin derivative having mTOR inhibiting properties or rapamycin in conjunction with one or more active co-agents selected from an EDG-receptor agonist having lymphocyte depleting properties;
- a cox-2 inhibitor;
- pimecrolimus;
- a cytokine inhibitor;
- a chemokine inhibitor;
- an antiproliferative agent;
- a statin, a protein, growth factor or compound stimulating growth factor production that will enhance endothelial regrowth of the luminal endothelium;
- a matrix metalloproteinase inhibitor;
- a somatostatin analogue;
- an aldosterone synthetase inhibitor or aldosterone receptor blocker;
- and a compound inhibiting the renin-angiotensin system.
A method for stabilizing vulnerable plaques in blood vessels of a subject in need of such a stabilization comprising administering to said patient a therapeutically effective amount of rapamycin or a rapamycin derivative having mTOR inhibiting properties, optionally in conjunction with one or more active co-agents and/or a controlled delivery from a drug delivery device or system of a therapeutically effective amount of rapamycin or a rapamycin derivative having mTOR inhibiting properties, optionally in conjunction with one or more active co-agents.
A method for preventing or treating restenosis in a diabetic patient comprising administering to said patient a therapeutically effective amount of rapamycin or a rapamycin derivative having mTOR inhibiting properties, optionally in conjunction with one or more active co-agents, and/or a controlled delivery from a drug delivery device or system of a therapeutically effective amount of rapamycin or a rapamycin derivative having mTOR inhibiting properties, optionally in conjunction with one or more active co-agents.
17 A method for the prevention or reduction of vascular access dysfunction in association with the insertion or repair of an indwelling shunt, fistula or catheter, or actual treatment, in a subject in need thereof, which comprises administering to the subject rapamycin or a rapamycin derivative having mTOR inhibiting properties, optionally in conjunction with one or more active co-agents, and/or a controlled delivery from a drug delivery device or system of a therapeutically effective amount of rapamycin or a rapamycin derivative having mTOR inhibiting properties, optionally in conjunction with one or more other active co-agents.
A method according to claim 17 comprising the controlled delivery from a drug delivery device or system wherein the drug delivery device or system comprises i) a medical device adapted for local application or administration of an active ingredient in hollow tubes and ii) an active ingredient comprising a therapeutic dosage of a rapamycin derivative having mTOR inhibiting properties or rapamycin, in conjunction with a therapeutic dosage of one or more active co-agents selected from a different immunosuppressant;
- an EDG-receptor agonist having lymphocyte depleting properties;
- an anti-inflammatory agent;
- an anti-thrombotic or anti-coagulant agent;
- an antiproliferative agent;
- a statin;
- a protein, growth factor or compound stimulating growth factor production that will enhance endothelial regrowth of the luminal endothelium;
- a matrix metalloproteinase inhibitor;
- a modulator of kinases;
- a compound stimulating the release of NO or a NO donor;
- a somatostatin analogue;
- an aldosterone synthetase inhibitor or aldosterone receptor blocker;
- a compound inhibiting the renin-angiotensin system;
- and mycophenolic acid or salt or prodrug thereof;
- each being releasably affixed to the medical device.
A method according to claim 17 comprising the controlled delivery from a drug delivery device or system wherein the drug delivery device or system comprises i) a medical device adapted for local application or administration of an active ingredient in hollow tubes and ii) an active ingredient comprising a therapeutic dosage of a rapamycin derivative having mTOR inhibiting properties or rapamycin, in conjunction with a therapeutic dosage of one or more active co-agents selected from an EDG-receptor agonist having lymphocyte depleting properties;
- a cox-2 inhibitor;
- pimecrolimus;
- a cytokine inhibitor;
- a chemokine inhibitor;
- an antiproliferative agent;
- a statin, a protein, growth factor or compound stimulating growth factor production that will enhance endothelial regrowth of the luminal endothelium;
- a matrix metalloproteinase inhibitor;
- a somatostatin analogue;
- an aldosterone synthetase inhibitor or aldosterone receptor blocker;
- and a compound inhibiting the renin-angiotensin system;
- each being releasably affixed to the medical device
A method according to claim 17 comprising the controlled delivery from a drug delivery device or system wherein sain drug delivery device or system comprises i) a medical device adapted for local application or administration of an active ingredient in hollow tubes and and ii) an active ingredient comprising a therapeutic dosage of a rapamycin derivative having mTOR inhibiting properties, in conjunction with a therapeutic dosage of one or more active co-agents selected from a calcineurin inhibitor and mycophenolic acid or a salt thereof or prodrug thereof, each being releasably affixed to the medical device.
Dependencies are inferred from the claim text.